The updated guidance for people aged 16 and over recommends using smaller amounts of intravenous fluid initially for those at risk of serious illness or death due to sepsis. Patients should be ...

The government is backing groundbreaking research to detect bowel cancer earlier and more effectively. Recent investments include £2.4 million for an AI blood test that can spot cancer with over 99% ...

Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in ...

This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk ...

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-mutated advanced non-small-cell lung cancer in adults after platinum-based chemotherapy. This is because ...

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...

Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. There is a simple discount patient ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments. There is ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...